CFO Julie Feder to depart Oct 25; VP Finance Amy Elazzouzi named interim CFO

Aura Biosciences, Inc.

CFO Julie Feder will resign effective Oct 25, 2024; no dispute or disagreement with company.
Feder will provide consulting services through Dec 31, 2024, and receive severance of 10 months base salary.
Amy Elazzouzi, VP Finance, appointed interim principal financial and accounting officer effective Oct 25.
Elazzouzi's annual base salary increased to $360,000; eligible for 30% target bonus.
Company will search for a permanent CFO during the interim period.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Amy Elazzouzi

interim principal financial officer and interim principal accounting officer

AURA · Aura Biosciences, Inc.

Effective: 2024-10-25
Filed: September 27, 2024, 7:59 PM ET

On September 25, 2024, the Board of Directors of the Company (the “Board”) designated Amy Elazzouzi, the Company’s Vice President, Finance, as the Company’s interim principal financial officer and interim principal accounting officer, in each case, effective on the Transition Date, to serve in such roles during the pendency of the Company’s search for a new Chief Financial Officer.

Departed (interim)

Julie Feder

Chief Financial Officer

AURA · Aura Biosciences, Inc.

Effective: 2024-10-25
Successor: Amy Elazzouzi
Filed: September 27, 2024, 7:59 PM ET

On September 23, 2024, Julie Feder notified Aura Biosciences, Inc. (the “Company”) of her departure from her role at the Company as an employee and Chief Financial Officer, effective as of October 25, 2024 (the “Transition Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Amy Elazzouzi was appointed as interim principal financial officer and interim principal accounting officer at Aura Biosciences, Inc..

Action: appointed
Role: interim principal financial officer and interim principal accounting officer

Exact text from the filing

On September 25, 2024, the Board of Directors of the Company (the “Board”) designated Amy Elazzouzi, the Company’s Vice President, Finance, as the Company’s interim principal financial officer and interim principal accounting officer, in each case, effective on the Transition Date, to serve in such roles during the pendency of the Company’s search for a new Chief Financial Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Julie Feder departed as Chief Financial Officer at Aura Biosciences, Inc..

Action: notified departure
Role: Chief Financial Officer

Exact text from the filing

On September 23, 2024, Julie Feder notified Aura Biosciences, Inc. (the “Company”) of her departure from her role at the Company as an employee and Chief Financial Officer, effective as of October 25, 2024 (the “Transition Date”).

View on SEC.gov

Aura Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-227950

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.